# A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

> **NCT04398134** · PHASE2 · TERMINATED · sponsor: **Assembly Biosciences** · enrollment: 88 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ABI-H2158
- **DRUG:** Placebo
- **DRUG:** Entecavir (ETV)

## Key facts

- **NCT ID:** NCT04398134
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-28
- **Primary completion:** 2021-10-14
- **Final completion:** 2021-12-28
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Study stopped due to a safety signal of drug-induced liver injury in subjects receiving 2158
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04398134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04398134, "A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04398134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*